| Clinical data | |
|---|---|
| Other names | MLD-41; MLD; N1-Methyl-Lysergic Acid Diethylamide; 1-Methyl-LSD; 1-Methyl-N,N-Diethyllysergamide; Methyl-LSD |
| Routes of administration | Oral |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H27N3O |
| Molar mass | 337.467 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
MLD-41, also known as 1-methyl-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It has about 33% of the psychoactive potency of LSD. It has been studied with regard to cross-tolerance with LSD. Extensive metabolism of other 1-methylated lysergamides to their secondary amine derivatives, for instance methysergide (1-methylmethylergometrine) conversion into methylergometrine, has been observed.
MLD-41 produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and with only slightly lower potency than LSD.
MLD-41 is not a controlled substance in Canada as of 2025.
| Ergolines (incl. lysergines) |
|
|---|---|
| Clavines (6,8-dimethylergolines) | |
| Lysergamides (lysergic acid amides) |
|
| Ergopeptines (peptide ergolines) |
|
| Partial ergolines |
|
| Related compounds | |
| Natural sources |
|